Advances in Targeting Cancer-Associated Genes by Designed siRNA in Prostate Cancer

Short interfering RNAs (siRNAs) have provided novel insights into the field of cancer treatment in light of their ability to specifically target and silence cancer-associated genes. In recent years, numerous studies focus on determining genes that actively participate in tumor formation, invasion, a...

Full description

Saved in:
Bibliographic Details
Published inCancers Vol. 12; no. 12; p. 3619
Main Authors Bahreyni, Amirhossein, Luo, Honglin
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 03.12.2020
MDPI
Subjects
Cancer therapies
cancer-associated genes
Cell growth
delivery
Gene silencing
Kinases
Metastases
Mutation
nanoparticle
Nanotechnology
Prostate cancer
Review
siRNA
delivery
nanoparticle
prostate cancer
siRNA
cancer-associated genes
Online AccessGet full text

Cover

More Information
Summary:Short interfering RNAs (siRNAs) have provided novel insights into the field of cancer treatment in light of their ability to specifically target and silence cancer-associated genes. In recent years, numerous studies focus on determining genes that actively participate in tumor formation, invasion, and metastasis in order to establish new targets for cancer treatment. In spite of great advances in designing various siRNAs with diverse targets, efficient delivery of siRNAs to cancer cells is still the main challenge in siRNA-mediated cancer treatment. Recent advancements in the field of nanotechnology and nanomedicine hold great promise to meet this challenge. This review focuses on recent findings in cancer-associated genes and the application of siRNAs to successfully silence them in prostate cancer, as well as recent progress for effectual delivery of siRNAs to cancer cells.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers12123619